



PRESS RELEASE

Published: 2026-02-18

Inhalation Sciences receives new IRS order for Dissolv/It® worth approximately EUR 139,000

Inhalation Sciences Sweden AB (ISAB) today announces that it has received an order valued at approximately EUR 139,000 (approximately SEK 1.5 million) for an IRS (Inhalation Research Services) for Dissolv/It® from a recurring customer and major international pharmaceutical company. The company is a global developer and manufacturer of complex generics and specialty medicines, with a strong presence in both established and emerging markets, that will use ISAB's technology to generate high-quality preclinical data for inhaled drug formulations.

The project includes Dissolv/It® studies on several test items, with method optimisation and repeated experiments for reliability carried out at Inhalation Sciences' laboratories at Novum Science Park in Huddinge, Sweden

Dissolv/It® is ISAB's proprietary in vitro dissolution-absorption system, designed to closely mimic the environment of the human lung. By combining precise aerosol deposition via PreciseInhale® with a dynamic flow-through dissolution and absorption setup, Dissolv/It® enables detailed and physiologically relevant characterization of inhaled formulations, for both new chemical entities and generic products.

"We are pleased that such a leading global pharmaceutical company has chosen to use our Dissolv/It platform again for this important inhalation study. This order confirms the growing recognition of our advanced in vitro technologies as a key resource for generating decision-critical data in inhalation drug development, from early-stage candidate selection through to rigorous comparison of generic formulations", says Manoush Masarrat, CEO of Inhalation Sciences.

For more information, please contact:

Manoush Masarrat, CEO

Phone: +46 (0) 73 628 9153

E-mail: manoush.masarrat@inhalation.se

About Inhalation Sciences Sweden AB (publ)

Inhalation Sciences is a cutting-edge Contract Research Organization (CRO) specializing in inhalation drug development. Leveraging our proprietary technology platform, PreciseInhale®, we empower our clients to de-risk and accelerate their R&D pipelines by delivering high-resolution, predictive data early in the development process.

This disclosure contains information that Inhalation Sciences is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was

submitted for publication, through the agency of the contact person, on February 18, 2026 at 09:10.